TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12031825

Group type: EXPERIMENTAL
Intervention: 10 g n-3 PUFA for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: 100 mg ASA (intravenous)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: n-3 PUFA and ASA combination
Number of subjects: 18
Study: 10435398

Group type: EXPERIMENTAL
Intervention: High dose isradipine (0.21 mg/kg orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-dose d-methamphetamine (0.21 mg/kg orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-dose d-methamphetamine (0.42 mg/kg orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7594092

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 214
Study: 2138405

Group type: EXPERIMENTAL
Intervention: Home‐Help Group (frequent contacts from diet leader)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Help Group (no caretaker-directed communications)
Number of subjects: 0
Study: 371034

Group type: EXPERIMENTAL
Intervention: Bicitropeptide
Number of subjects: 106

Group type: COMPARATOR
Intervention: Antacid (Maalox)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 6137694

Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 88
Study: 30756527

Group type: EXPERIMENTAL
Intervention: 120 mg/d ifenprodil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg/d ifenprodil
Number of subjects: 0
Study: 29576595

Group type: EXPERIMENTAL
Intervention: Enriched circulating endothelial progenitor cells (ECEPCs) injected into the gastrocnemius of the affected limb.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bone marrow mononuclear cells (BM‐MNC) injected into the gastrocnemius of the affected limb.
Number of subjects: 40
Study: 26511777

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 25304219

Group type: EXPERIMENTAL
Intervention: 2% homatropine hydrobromide
Number of subjects: 14

Group type: COMPARATOR
Intervention: 2.5% phenylephrine hydrochloride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0.3% hydroxypropyl methylcellulose)
Number of subjects: 14
Study: 22176867

Group type: EXPERIMENTAL
Intervention: Vinflunine (VFL) therapy
Number of subjects: 179
Study: 20007944

Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart (IAsp) administered immediately before each meal
Number of subjects: 322

Group type: COMPARATOR
Intervention: Human insulin administered 30 min before each meal
Number of subjects: 322
Study: 17612657

Group type: COMPARATOR
Intervention: Intracoronary saline solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adenosine (12 microg/bolus)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of adenosine (12 microg/bolus) and sodium nitroprusside (50 microg/bolus)
Number of subjects: 75
Study: 16035081

Group type: EXPERIMENTAL
Intervention: rFVIIa (20, 40, or 80 microg/kg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 11926599

Group type: EXPERIMENTAL
Intervention: Acupuncture at four local points around the knee and one distal point
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 10890777

Group type: EXPERIMENTAL
Intervention: AAV-CFTR
Number of subjects: 10
Study: 7890239

Group type: EXPERIMENTAL
Intervention: 30 mg/kg ALA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 60 mg/kg ALA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Red laser light (628 nm) treatment after ALA administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 18
Study: 1835398

Group type: EXPERIMENTAL
Intervention: Clodronate (1.6g orally daily for 18 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6119766

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice a day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: L-hyoscyamine 0.6 mg twice a day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31422845

Group type: EXPERIMENTAL
Intervention: Newly developed computerized intervention aimed at decreasing perceived burdensomeness and thwarted belongingness
Number of subjects: 46

Group type: COMPARATOR
Intervention: Repeated contact control condition
Number of subjects: 46
Study: 27600941

Group type: EXPERIMENTAL
Intervention: Social Recovery Cognitive Behavioural Therapy (SRCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both SRCBT and Treatment as usual
Number of subjects: 0
Study: 26813869

Group type: EXPERIMENTAL
Intervention: Conventional height‐based balloon reference sizing (HBRS)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Echocardiographic measurement of the diastolic inter‐commissural diameter (EBRS)
Number of subjects: 128
Study: 24359938

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral paracetamol (15 mg/kg every 6 hours for 3 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 90
Study: 21292439

Group type: EXPERIMENTAL
Intervention: Voice therapy after BTX‐A injection
Number of subjects: 31

Group type: COMPARATOR
Intervention: BTX‐A injection
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham voice therapy after BTX‐A injection
Number of subjects: 31
Study: 19057384

Group type: EXPERIMENTAL
Intervention: Mixed-model prediction
Number of subjects: 509

Group type: COMPARATOR
Intervention: Individual-level estimates
Number of subjects: 509

Group type: COMPARATOR
Intervention: Group-level estimates
Number of subjects: 509
Study: 17996121

Group type: EXPERIMENTAL
Intervention: Artemether plus lumefantrine (AL)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (AS+AQ)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 157
Study: 16382596

Group type: EXPERIMENTAL
Intervention: iBond GI (Heraeus Kulzer, Inc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (3M ESPE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xeno III (Caulk/Dentsply)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrophobic resin layer added to self-etching adhesives
Number of subjects: 0

Group type: COMPARATOR
Intervention: UniFil Bond (GC America)
Number of subjects: 0
Study: 14647791

Group type: COMPARATOR
Intervention: Healthy carriers
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Children with pneumonia
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 911
Study: 9709956

Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I; 3 microg/kg-h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 11
Study: 7597021

Group type: EXPERIMENTAL
Intervention: Health promotion activities (nutrition programs, smoking control programs)
Number of subjects: 20801

Group type: EXPERIMENTAL
Intervention: Dietary habits
Number of subjects: 20801

Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 20801

Group type: EXPERIMENTAL
Intervention: Environmental support for dietary behavior change
Number of subjects: 20801

Group type: EXPERIMENTAL
Intervention: Perceived support for smoking cessation
Number of subjects: 20801
Study: 2215986

Group type: EXPERIMENTAL
Intervention: Halothane (0.8% end-tidal) with atracurium (0.35 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isoflurane (1% end-tidal) with atracurium (0.35 mg/kg)
Number of subjects: 32
Study: 626731

Group type: EXPERIMENTAL
Intervention: Pulsed oxytocin infusion (infused for one minute every ten minutes using a modified Cardiff Infusion System Mark III)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 28
Study: 30261783

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet in pregnancy
Number of subjects: 265
Study: 31048449

Group type: EXPERIMENTAL
Intervention: Accelerated medical assessment and surgical repair (goal within 6 h)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3000
Study: 28973362

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by allo‐HSCT (HSCT group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy alone (chemotherapy group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy (adult regimen)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pediatric regimens
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High WBC count and CD20 positivity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low WBC count and absence of CD20
Number of subjects: 96
Study: 25764173

Group type: EXPERIMENTAL
Intervention: Cerebral malaria (CM)
Number of subjects: 45
Study: 23106093

Group type: EXPERIMENTAL
Intervention: Exercise therapy (2 hours of structured exercise weekly for 6 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Occupational therapy (2 hours weekly for 6 months)
Number of subjects: 63
Study: 21571547

Group type: EXPERIMENTAL
Intervention: PVI + SET
Number of subjects: 70

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 70
Study: 18844760

Group type: EXPERIMENTAL
Intervention: 30-minute rest period
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment (perindopril, amlodipine, or labetalol)
Number of subjects: 549
Study: 16140433

Group type: EXPERIMENTAL
Intervention: M01ZH09 vaccine at 5 x 10(9) CFU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M01ZH09 vaccine at 5 x 10(8) CFU
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M01ZH09 vaccine at 5 x 10(7) CFU
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 13680163

Group type: EXPERIMENTAL
Intervention: Megestrol (total dose 320 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (total dose 30 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10897370

Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 micrograms/kg)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Combination of Ivermectin and Albendazole (400 mg)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1425
Study: 8775253

Group type: EXPERIMENTAL
Intervention: Depot goserelin acetate, 3.6 mg, subcutaneously at 4-weekly intervals
Number of subjects: 72

Group type: COMPARATOR
Intervention: Danazol, 600 mg/day
Number of subjects: 72
Study: 1486391

Group type: EXPERIMENTAL
Intervention: Intravenous epirubicin 90 mg/m2 every 28 days
Number of subjects: 29
Study: 6419958

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 31470815

Group type: EXPERIMENTAL
Intervention: Augmented Prescribed Exercise Program (APEP) - additional exercise sessions (20-30 min, 4-5 times/week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (including physiotherapy)
Number of subjects: 35
Study: 29893144

Group type: EXPERIMENTAL
Intervention: Glucose-dependent therapies (Strategy A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Glucose-independent therapies (Strategy B)
Number of subjects: 47
Study: 27378704

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 148

Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 148
Study: 25956287

Group type: EXPERIMENTAL
Intervention: Coumarin anticoagulants
Number of subjects: 847
Study: 23550910

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX) adhesive
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2.0% chlorhexidine digluconate (CHX) therapeutic primer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group without CHX
Number of subjects: 120
Study: 21266513

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (10 μg HBvaxPRO, 0-1-3 week schedule)
Number of subjects: 761

Group type: COMPARATOR
Intervention: Standard vaccination schedule (10 μg HBvaxPRO, 0-4-24 week schedule)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule
Number of subjects: 761
Study: 19295936

Group type: EXPERIMENTAL
Intervention: Presence of restaurants in census tracts
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Presence of other food service places in census tracts
Number of subjects: 132

Group type: COMPARATOR
Intervention: Presence of convenience stores and lower neighborhood SES
Number of subjects: 132
Study: 16825691

Group type: EXPERIMENTAL
Intervention: Drink B (CPP-enriched preparation, 1.7 g CPP, 400 mg Ca as calcium lactate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Drink C (CPP-enriched preparation, 1.7 g CPP, 400 mg Ca as calcium lactate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Drink A (calcium lactate drink, 400 mg Ca as lactate)
Number of subjects: 15
Study: 12860542

Group type: EXPERIMENTAL
Intervention: Trapezius muscle activity in athletes with impingement
Number of subjects: 69

Group type: COMPARATOR
Intervention: Trapezius muscle activity in control subjects (no impingement)
Number of subjects: 69
Study: 10833865

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9106276

Group type: EXPERIMENTAL
Intervention: Visual cues at four locations occurring simultaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding a visual alerting signal to an auditory signal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory signal used to modulate alertness level during a covert orienting task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice task
Number of subjects: 0
Study: 7845645

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Betoxycaine
Number of subjects: 212

Group type: COMPARATOR
Intervention: Metipranolol
Number of subjects: 212

Group type: COMPARATOR
Intervention: Indomethacin suspension
Number of subjects: 212
Study: 2842842

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 246
Study: 29304325

Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: L-PRF-plus-HA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 28070894

Group type: EXPERIMENTAL
Intervention: TAS-102 tablets (60 mg; 3 × 20-mg tablets)
Number of subjects: 46

Group type: COMPARATOR
Intervention: TAS-102 oral solution (60 mg)
Number of subjects: 46
Study: 25824212

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) at 2.5 mg/kg of body weight/12 h for 60 days
Number of subjects: 39
Study: 25133413

Group type: EXPERIMENTAL
Intervention: theory‐based social‐cognitive intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: passive waiting‐list control group
Number of subjects: 280

Group type: COMPARATOR
Intervention: active control intervention designed to motivate physical activity
Number of subjects: 280
Study: 22572644

Group type: EXPERIMENTAL
Intervention: High-fat yogurt
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-fat yogurt
Number of subjects: 11
Study: 20981000

Group type: EXPERIMENTAL
Intervention: MK-0249 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MK-0249 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18401299

Group type: EXPERIMENTAL
Intervention: Two eyedrops of cyclopentolate 0.5% at a 10-min interval
Number of subjects: 36

Group type: COMPARATOR
Intervention: Three eyedrops of cyclopentolate 0.5% at a 5-min interval
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both protocols (two drops and three drops)
Number of subjects: 36
Study: 15845499

Group type: EXPERIMENTAL
Intervention: One dose of tetravalent polysaccharide vaccine for children >/=24 months old
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of tetravalent polysaccharide vaccine for children </=18 months old
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age-dependent increases in postvaccination IgG levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children >/=2 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children who were 4 years of age
Number of subjects: 0
Study: 11918735

Group type: EXPERIMENTAL
Intervention: 40 mmol/L lactate dialysate
Number of subjects: 8

Group type: COMPARATOR
Intervention: 35 mmol/L lactate dialysate
Number of subjects: 8
Study: 10342622

Group type: EXPERIMENTAL
Intervention: Intra-articular Sm-153 PHYP combined with 40 mg triamcinolone hexacetonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: 40 mg intra-articular triamcinolone hexacetonide alone
Number of subjects: 24
Study: 9196767

Group type: EXPERIMENTAL
Intervention: Single oral dose of 500 mg artemisinin with a single 500 mg oral dose of mefloquine (AM)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Mefloquine therapy alone (M)
Number of subjects: 231
Study: 1435916

Group type: EXPERIMENTAL
Intervention: Noninvasive measurement of pulse-amplitude ratio during Valsalva maneuver
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Noninvasive measurement of pulse-amplitude ratio
Number of subjects: 34
Study: 3457047

Group type: EXPERIMENTAL
Intervention: 0.1% SnF2
Number of subjects: 437

Group type: COMPARATOR
Intervention: 0.05% NaF
Number of subjects: 437
Study: 30504097

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo acupuncture (sham intervention)
Number of subjects: 144
Study: 29421012

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Type 1 myocardial infarction
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Overall myocardial infarction events
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Troponin increase >10× the upper limit of normal
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 1327
Study: 27806060

Group type: EXPERIMENTAL
Intervention: Minimal Smoke‐Free Homes intervention delivered by trained 2‐1‐1 information and referral specialists (3 mailings and 1 coaching call)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Minimal Smoke‐Free Homes intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 24206527

Group type: EXPERIMENTAL
Intervention: Laropiprant 40mg, clopidogrel 75mg, and aspirin 80mg (Study 1) or 81mg (Study 2) once daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, clopidogrel 75mg, and aspirin 80mg (Study 1) or 81mg (Study 2) once daily for 7 days
Number of subjects: 0
Study: 23043882

Group type: EXPERIMENTAL
Intervention: MTA Fillapex and gutta percha
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: AH Plus and gutta percha
Number of subjects: 51
Study: 20889603

Group type: EXPERIMENTAL
Intervention: Symptom diary group (daily use for 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no diary use)
Number of subjects: 40
Study: 18552684

Group type: EXPERIMENTAL
Intervention: Aerosol antibiotic (AA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (aerosol saline)
Number of subjects: 43
Study: 15876307

Group type: EXPERIMENTAL
Intervention: Prednisolone (oral glucocorticoid), 1 dose per day for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 0
Study: 12499279

Group type: EXPERIMENTAL
Intervention: High EGFR-expressing HNSCCs (>median MOD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low EGFR-expressing HNSCCs
Number of subjects: 155
Study: 10087548

Group type: EXPERIMENTAL
Intervention: CapSure Z leads (1.2 mm2 surface area; steroid-eluting)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CapSure SP leads (5.8 mm2 surface area; steroid-eluting)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CapSure leads (8 mm2 surface area; steroid-eluting)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Target Tip leads (8 mm2 surface area; no steroid elution)
Number of subjects: 188
Study: 7723402

Group type: EXPERIMENTAL
Intervention: Single dose of recombinant human granulocyte‐macrophage colony‐stimulating factor (rhGM‐CSF) 5 micrograms/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three doses of rhGM‐CSF administered subcutaneously every 24 h
Number of subjects: 0
Study: 8225680

Group type: EXPERIMENTAL
Intervention: Phentermine HCl capsules (Minobese Forte)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Phentermine base capsules (Duromine)
Number of subjects: 21
Study: 2858707

Group type: EXPERIMENTAL
Intervention: Mass screening with single-view mammography every 2 or 3 years depending on age
Number of subjects: 134867

Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 134867

Group type: EXPERIMENTAL
Intervention: Mass screening with single-view mammography
Number of subjects: 134867
Study: 31951263

Group type: EXPERIMENTAL
Intervention: Early intervention group (n = 80) receiving one-on-one physical therapy 8 times over 6 weeks and daily home exercises with wearable sensors
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care group (n = 80) receiving the same intervention after a 6- to 8-week wait period with wearable sensors
Number of subjects: 160
Study: 29122571

Group type: EXPERIMENTAL
Intervention: 360º video using Samsung GearVR virtual-reality headsets
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D video on a 75-inch television
Number of subjects: 40
Study: 24165269

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (4 sessions over 12 months)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430
Study: 21897113

Group type: EXPERIMENTAL
Intervention: Hypocaloric low glycemic index (LGI) diet (GI:60)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hypocaloric high glycemic index (HGI) diet (GI:90)
Number of subjects: 22